COMPOSITIONS OF 5-HT3 ANTAGONISTS AND DOPAMINE D2 ANTAGONISTS FOR TREATMENT OF DOPAMINE-ASSOCIATED CHRONIC CONDITIONS
The present invention provides novel compositions comprising a combination of a 5-HT 3 receptor antagonist and a selective dopamine D 2 receptor antagonist for the treatment of obsessive, impulsive and compulsive behavioral activities and other dopamine pathway-associated disorders or conditions. Preferably, the pharmaceutical compositions of the present invention comprise amounts of the 5-HT 3 receptor antagonist ondansetron and a selective dopamine D 2 receptor antagonist, such as risperidone or olanzapine, that are sufficient to control a subjects obsessive, impulsive and compulsive behavioral activities. Kits comprising the combination of antagonists for the treatment of addictive disorders such as alcohol dependence are also provided.
1 . A pharmaceutical composition comprising about 0.2 to about 8.0 mg of ondansetron and about 0.1 to about 0.5 mg of risperidone.
2 . The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition comprises about 0.2 to about 0.8 mg of ondansetron.
3 . The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition comprises about 0.325 mg of ondansetron.
4 . The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition comprises about 0.65 mg of ondansetron.
5 . The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition comprises about 0.5 mg of risperidone.
6 . A method for treating obsessive, impulsive, and compulsive behavioral activities in a patient, said method comprising the steps of:
providing a pharmaceutical composition comprising about 0.2 to about 8.0 mg of ondansetron and about 0.1 to about 0.5 mg of risperidone; and
administering the composition to the patient.
7 . The method of claim 6 , wherein the pharmaceutical composition comprises about 0.2 to about 0.8 mg of ondansetron.
8 . The method of claim 6 , wherein the pharmaceutical composition comprises about 0.325 mg of ondansetron.
9 . The method of claim 6 , wherein the pharmaceutical composition comprises about 0.65 mg of ondansetron.
10 . The method of claim 6 , wherein the pharmaceutical composition comprises about 0.5 mg of risperidone.
11 . The method of claim 6 , wherein the obsessive, impulsive, and compulsive behavioral activities include substance abuse or substance dependence.
12 . A method for treating obsessive, impulsive, and compulsive behavioral activities in a patient, said method comprising the steps of:
providing a pharmaceutical composition comprising about 0.2 to about 8.0 mg of ondansetron and about 0.5 to about 7.5 mg of olanzapine; and
administering the composition to the patient.
13 . The method of claim 12 , wherein the pharmaceutical composition comprises about 0.2 to about 8.0 mg of ondansetron.
14 . The method of claim 12 , wherein the pharmaceutical composition comprises about 1 mg of olanzapine.
15 . The method of claim 12 , wherein the pharmaceutical composition comprises about 5 mg of olanzapine.
16 . The method of claim 12 , wherein the pharmaceutical composition comprises about 0.325 mg of ondansetron.
17 . The method of claim 12 , wherein the pharmaceutical composition comprises about 0.65 mg of ondansetron.
18 . The method of claim 12 , wherein the obsessive, impulsive, and compulsive behavioral activities include substance abuse or substance dependence.